All In Biotech

Free tool

FAERS Monitor: Vizimpro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211288 or its brand name (Vizimpro, Dacomitinib). Reports on generic versions are filed under their own applications.

Reports

749

Serious

692

92% of reports

Hospitalization

215

Death reported

330

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death238
  • diarrhoea121
  • rash115
  • neoplasm progression78
  • paronychia58
  • blood pressure increased47
  • malignant neoplasm progression45
  • pruritus36
  • off label use34
  • dyspnoea32
  • decreased appetite29
  • vomiting28
  • pain27
  • carcinoembryonic antigen increased26
  • drug interaction26

Reports by year received

View as table
YearReports
201211
201314
20148
20153
20162
20171
20185
201950
202077
2021131
2022207
2023128
202455
202541
202616

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,410 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
carcinoembryonic antigen increasedSignal26382.0261.29,377
paronychiaSignal58375.6292.821,017
neoplasm progressionSignal7863.151.24,706
malignant neoplasm progressionSignal4512.39.3460
blood pressure increasedSignal478.66.5312
deathSignal2387.87.01,454
rashSignal1157.46.3644
diarrhoeaSignal1215.34.5427
drug interactionSignal264.63.270
decreased appetiteSignal293.52.550
pruritusSignal362.61.935
vomiting281.71.27
dyspnoea321.61.17
pain271.20.91
off label use341.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.